GO
Loading...

Allergan Inc

More

  • Valeant on Wednesday offered to pay $58.30 per Allergan share in cash, about $10 higher than its previous offer of $48.30. The new offer values Allergan at $166.16 per share as of Tuesday's closing price, and is about 8.6 percent higher than the previous bid of $153 as on April 22 when Valeant first made its offer.

  • Valeant increases bid for Botox-maker Allergan Wednesday, 28 May 2014 | 6:13 AM ET

    Valeant on Wednesday offered to pay $58.30 per Allergan share in cash, about 21 percent higher than its previous offer of $48.30. The stock component of the offer remains the same at 0.83 of a Valeant share for each to Allergan share held.

  • Hedge fund growth crushed in choppy markets Wednesday, 21 May 2014 | 11:22 AM ET

    A stellar 2013 boosted confidence for stockpickers, but hedge funds are suffering their worst start to a year since the financial crisis.

  • Midday movers: General Motors, Caterpillar & More Tuesday, 20 May 2014 | 1:01 PM ET

    Some of Tuesday's midday movers:

  • LAVAL, QUEBEC, May 20- Canada's Valeant Pharmaceuticals International said on Tuesday it will not make an all-cash bid for drugmaker Allergan Inc as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker.

  • May 20- Canada's Valeant Pharmaceuticals International Inc said it will not make an all-cash bid for drugmaker Allergan Inc as many had expected last week when the company said it would improve its cash and stock offer for the Botox maker.

  • For activist investors, a wide reporting window Tuesday, 20 May 2014 | 9:05 AM ET
    Bill Ackman

    How was it possible that Bill Ackman's Pershing Square Capital had become Allergan's largest shareholder without anyone knowing? The NYT reports.

  • May 20- Canada's Valeant Pharmaceuticals International Inc said its sweetened offer for drugmaker Allergan Inc would not be an all-cash bid as was expected. Valeant, which plans to announce its improved offer on May 28, had launched a $47 billion unsolicited bid on April 22, along with activist investor William Ackman.

  • Ackman: Allergan CEO has 'disabling' deal conflict Monday, 19 May 2014 | 10:23 AM ET
    Bill Ackman

    Activist investor William Ackman told Allergan's board that the CEO has a 'disabling' conflict of interest because a takeover means losing his job.

  • May 19- Activist investor William Ackman said on Monday that Allergan Inc's chief executive has a "disabling" conflict of interest because accepting a takeover by Valeant Pharmaceuticals International likely means he would lose his job. Ackman and Valeant launched a $47 billion takeover of the company on April 22, but so far Allergan has rejected the advances.

  • May 19- Activist investor William Ackman said on Monday in a letter to takeover target Allergan Inc's board of directors that the top executive has a "disabling" conflict of interest because accepting a takeover means losing the top job.

  • Chanos: These are the best shorts in bull market Thursday, 15 May 2014 | 2:42 PM ET
    Jim Chanos, president and founder of Kynikos Associates.

    Jim Chanos of Kynikos Associates says he'll continue to bet against Caterpillar and China, as well as a few other names.

  • May 13- Valeant Pharmaceuticals International Inc said on Tuesday it will sweeten its unsolicited $47 billion offer for drugmaker Allergan Inc, and activist shareholder Pershing Square Capital Management said it would ask for a non-binding vote to pressure Allergan to the negotiating table.

  • May 13- Pershing Square Capital Management, led by investor William Ackman, went directly to Allergan Inc shareholders on Tuesday and asked them to vote on its joint $47 billion bid with Valeant Pharmaceuticals International for the company. Allergan rejected the offer on Monday.

  • Midday movers: Microsoft, Puma, Whirlpool & More Tuesday, 13 May 2014 | 12:39 PM ET

    Tuesday's midday movers:

  • May 13- Valeant Pharmaceuticals International Inc said on Tuesday it will "improve" its unsolicited $47 billion takeover offer for drugmaker Allergan Inc, a day after the U.S. company rejected the bid.

  • Valeant to sweeten Allergan's 'cut and slash' offer Tuesday, 13 May 2014 | 8:44 AM ET
    Valeant Pharmaceuticals sign at the company's headquarters in Mississauga, Ontario.

    Valeant said it planned to "improve" its $47 billion takeover offer for drugmaker Allergan, a day after the U.S. company rejected the bid.

  • UPDATE 1-Valeant plans to "improve" offer for Allergan Tuesday, 13 May 2014 | 8:43 AM ET

    May 13- Valeant Pharmaceuticals International Inc said on Tuesday it will "improve" its $47 billion takeover offer for drugmaker Allergan Inc, a day after the U.S. company rejected the bid. Allergan put in a so-called "poison pill" within days to slow Ackman from increasing his nearly 10 percent stake in Allergan.

  • Valeant says plans to "improve" offer for Allergan Tuesday, 13 May 2014 | 8:13 AM ET

    May 13- Valeant Pharmaceuticals International Inc said it planned to "improve" its $47 billion takeover offer for drugmaker Allergan Inc, a day after the U.S. company rejected the bid. Canada's Valeant said it remained committed to getting the deal done but would remain "financially disciplined."

  • *Hillshire to buy Pinnacle Foods for $6.6 billion. Biogen Idec jumped 4.8 percent to $300.54 and TripAdvisor Inc rose 5.8 percent to $89.51. Twitter gained 5.9 percent to $33.94 after news reports that brokerage SunTrust raised its rating on the stock to "buy."